No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HQY240517P70000
- 0.05
- -0.48-90.57%
15min DelayClose May 10 15:58 ET
0.05High0.05Low
0.05Open0.53Pre Close1 Volume2 Open Interest70.00Strike Price5.00Turnover43.75%IV-9.54%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.0302Delta0.0163Gamma1546.60Leverage Ratio-0.0224Theta-0.0003Rho-46.65Eff Leverage0.0065Vega
Intraday
- 5D
- 1D
News
HealthEquity Sets Date to Announce First Quarter Results
Presentation at ConferencesDRAPER, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") cust
Healthequity (HQY): A Strong Buy on Digital Wallet Expansion and Enhanced Profitability
20 Fastest Growing Fintech Companies In 2024
Team Member Feedback Earns HealthEquity Workplace Culture Recognition
DRAPER, Utah, May 02, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY), the nation's largest Health Savings Account (HSA) custodian has received a Culture Excellence Award by Top Workplaces for the fourth
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Express News | HealthEquity Inc - Board Has Reduced Size of Board to 10 Members Effective Immediately Following 2024 Annual Meeting of Stockholders
Comments
HealthEquity's high P/S ratio could possibly be due to market expectations for future growth. The current justification for the high ratio lies on the low chance of decreased revenues, which investors expect to uphold share price.
Despite expenses reducing earnings last year, HealthEquity's future outlook remains positive. Unusual items don't typically recur, suggesting underestimated earning potential. The firm returned to profitability this year.
Despite HealthEquity's revenue growth and share price rise over three years, short-term underperformance and negative five-year returns are concerning. Fundamental improvements are required for shareholder confidence. Analyst forecasts could shed light on the company's future.
Read more